HIV Medicine

Euthanasia, physicians and HIV infected persons
pp. 1-2(2)
Author: Nathanson, V.

Euthanasia: from the perspective of HIV infected persons in Europe
pp. 3-10(8)
Authors: Andraghetti, R; Foran, S; Colebunders, R; Tomlinson, D; Vyras, P; Borleffs, Cj; Fleerackers, Y; Schrooten, W; Borchert, M

Molecular correlates in AIDS patients following antiretroviral therapy: diversified T-cell receptor repertoires and in vivo control of cytomegalovirus replication
pp. 11-19(9)
Authors: Worrell, S; Deayton, J; Hayes, P; Emery, Vc; Gotch, F; Gazzard, B; Larsson-Sciard, E-L

MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
pp. 20-26(7)
Authors: Katlama, C; Pellegrin, J-L; Lacoste, D; Aquilina, C; Raffi, F; Pialoux, G; Vittecoq, D; Raguin, G; Lantz, O; Mouroux, M; Calvez, V; Trylesinski, A; Montestruc, F; Dohin, E; Goehrs, Jm; Delfraissy, Jf

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial
pp. 27-34(8)
Authors: Katlama, C; Clotet, B; Plettenberg, A; Jost, J; Arasteh, K; Bernasconi, E; Jeantils, V; Cutrell, A; Stone, C; Purdon, S

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
pp. 35-42(8)
Authors: Battegay, M; Vernazza, Pl; Bernasconi, E; Flepp, M; Sendi, P; Erb, P; Malinverni, R; Jaccard, C; Morgenthaler, S; Bedoucha, V; Hirschel, B

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort
pp. 43-51(9)
Authors: Kirk, O; Gerstoft, J; Pedersen, C; Nielsen, H; Obel, N; Katzenstein, Tl; Mathiesen, L; Lundgren, Jd

Assessing the cost-effectiveness of HAART for adults with HIV in England
pp. 52-58(7)
Authors: Miners, Ah; Sabin, Ca; Trueman, P; Youle, M; Mocroft, A; Johnson, M; Beck, Ej

L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome
pp. 59-60(2)
Authors: Mauss, S; Schmutz, G

Response to the communication of M Hosp et al. on low-cost progression markers in HIV-1 seropositive Zambians
pp. 61-61(1)
Authors: Post, Fa; Wood, R; Maartens, G

Characteristics of doctor-patient relationship and implication on adherence to antiretroviral treatments
pp. 62-63(2)
Authors: Martini, M; Parazzini, F; Agnoletto, V